Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Collegium Pharmaceutical, Inc. (COLL) vs Evotec AG (EVO)

Collegium Pharmaceutical, Inc. and Evotec AG are both Drug Manufacturers Specialty & Generic companies. Collegium Pharmaceutical, Inc. is the larger, with a market value of $737.1M against $539.9M — 1.4× the size. Evotec AG has negative trailing earnings, so its P/E is not meaningful; Collegium Pharmaceutical, Inc. trades at 14.7×. Collegium Pharmaceutical, Inc. grew revenue faster over the last twelve months: 14.3% against 2.15%. Collegium Pharmaceutical, Inc. has the higher net margin (5.93% vs −26.2%) and the higher return on invested capital (7.85% vs 0.00%). Across the 19 metrics below, Collegium Pharmaceutical, Inc. leads on 12 and Evotec AG on 7.

Valuation

Metric COLL EVO Drug Manufacturers Specialty & Generic median
P/E 14.73 n/m 20.14
P/S 0.90 0.64 2.25
P/B 2.34 0.72 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 4.29 n/m 12.29
EV/Sales 2.07 0.65 2.56
Earnings yield 6.79% (40.90%) (2.99%)
Free cash flow yield (5.46%) (36.14%) 0.00%

Profitability

Metric COLL EVO Drug Manufacturers Specialty & Generic median
Gross margin 60.02% 11.42% 53.94%
Operating margin 19.48% (21.35%) 0.00%
Net margin 5.93% (26.20%) 0.00%
Free cash flow margin 40.62% 0.00% 0.00%
Return on equity 17.61% 0.00% (0.40%)
Return on assets 2.57% 0.00% (3.32%)
Return on invested capital 7.85% 0.00% 0.00%

Growth

Metric COLL EVO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 14.31% 2.15% 10.01%
EPS growth (last fiscal year) (6.99%) 44.89% —
Revenue growth, 5-year CAGR 20.28% 9.28% 6.74%
Net income growth, 5-year CAGR 18.64% 0.00% 0.00%

Health

Metric COLL EVO Drug Manufacturers Specialty & Generic median
Debt to equity 3.50 0.72 0.05
Current ratio 1.03 2.33 2.31
Net debt to EBITDA 1.00 (0.64) 0.85

Dividend

Metric COLL EVO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric COLL EVO Drug Manufacturers Specialty & Generic median
Market cap 737.06m 539.87m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack